Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Primary Prevention of Sudden Cardiac Death With Implantable Cardioverter-Defibrillator Therapy in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Assessment of Predictors of Left Atrial Volume Response to a Transcatheter InterAtrial Shunt Device (from the REDUCE LAP-HF Trial)

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Causes of Mortality in the Marfan Syndrome(from a Nationwide Register Study)

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Recurrent infective endocarditis versus first-time infective endocarditis after heart valve surgery

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Renal 123I-MIBG Uptake before and after Live-Donor Kidney Transplantation

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Differences in mortality in patients undergoing surgery for infective endocarditis according to age and valvular surgery

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Implantable cardioverter-defibrillator (ICD) therapy remains a corner stone of sudden cardiac death (SCD) prevention in patients with arrhythmogenic right ventricular cardiomyopathy (ARVC). We aimed to assess predictors of appropriate ICD therapies in the Scandinavian cohort of ARVC patients who received ICD for primary prevention of SCD. Study group comprised of 79 definite ARVC patients by 2010 Task Force criteria (60% male, age at ICD implant 39 ± 14 years) who were enrolled in the Nordic ARVC Registry and received an ICD for primary SCD prevention. The primary end point of appropriate ICD shock or death from any cause was assessed and compared with 137 definite ARVC patients who received ICD for secondary SCD prevention (74% male, age at ICD implant 42 ± 15 years). In the study group, 38% were ≤35 years of age at baseline, 25% had nonsustained ventricular tachycardia, and 29% had syncope at baseline. Major repolarization abnormality (hazard ratio = 4.00, 95% confidence interval 1.30 to 12.30, p = 0.015) and age ≤35 years (hazard ratio = 4.21, 95% confidence interval 1.49 to 11.85, p = 0.001) independently predicted the primary end point. The outcome did not differ between the primary prevention patients with either of these risk factors and the secondary prevention cohort (2% to 4% annual event rate) whereas patients without risk factors did not have any appropriate ICD shocks during follow-up. In conclusion, young age at ARVC diagnosis and major repolarization abnormality independently predict ICD shocks or death in the primary prevention ICD recipients and associated with the event rate similar to the one observed in the secondary prevention cohort. Our data indicate the benefit of ICD for primary prevention in patients with any of these risk factors.

Original languageEnglish
JournalThe American journal of cardiology
Volume123
Issue number7
Pages (from-to)1156-1162
Number of pages7
ISSN0002-9149
DOIs
Publication statusPublished - 1 Apr 2019

ID: 56978950